Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The California STEM Reporter.
Press releases published on August 6, 2025
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy
Safety Review Committee endorses escalation to 160 mg TUS dosing Cohorts with 120 mg, 80 mg, 40 mg TUS dosing completed with no dose-limiting toxicities Excellent safety and complete remissions (CRs) in some of the most difficult-to-treat AML populations …
BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates
Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end Expanded APJ agonist pipeline through option agreement for novel antibody and advancement of proprietary oral small molecules Strengthened discovery …
Surrozen to Present at Upcoming Healthcare Investor Conference
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and …
MKS Inc. Reports Second Quarter 2025 Financial Results
Revenue of $973 million, above the high end of guidance GAAP net income of $62 million and net income per diluted share of $0.92, each above the midpoint of guidance Adjusted EBITDA of $240 million, above the high end of guidance, and Non-GAAP net earnings …
Orezone Provides Notice of Q2-2025 Results
VANCOUVER, British Columbia, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (“Orezone”) will announce its second quarter 2025 results on Wednesday, August 13, 2025, after market close. The announcement will be followed …
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated …
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trial Enrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through Week 12 on track for Q4 2025 Ongoing …
GoHealth to Announce Strategic Capital and Governance Actions to Support Long-Term Value Creation and Second Quarter 2025 Results
CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, will announce strategic capital and governance actions to support long-term value …
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. …
Certara Reports Second Quarter 2025 Financial Results
RADNOR, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the second quarter of fiscal year 2025. Second Quarter Highlights: Revenue was $104.6 …
Silvaco Reports Second Quarter 2025 Financial Results
Achieved Gross Bookings of $12.91 Million and Revenue of $12.05 Million Landed 10 New Logos in Photonics, Automotive, Military, Foundry, and Power Achieved Trailing Twelve-Month ACV Growth of 26% SANTA CLARA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- …
Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update
Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year …
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) …
Veeco Reports Second Quarter 2025 Financial Results
Second Quarter 2025 Highlights: Revenue of $166.1 million, compared with $175.9 million in the same period last year GAAP net income of $11.7 million, or $0.20 per diluted share, compared with $14.9 million, or $0.25 per diluted share in the same period …
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2025, …
Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a …
Sprout Social Announces Second Quarter 2025 Financial Results
CHICAGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its second quarter ended June …
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with …
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash …
electroCore Announces Second Quarter 2025 Financial Results
Net sales of $7.4 million increased 20% vs. Q2’2024; YTD net sales of $14.1 million increased 22% vs. first half of 2024 Cash, cash equivalents, restricted cash, and marketable securities of $7.4 million as of June 30, 2025 Company to host a conference …